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Abstract
The demonstration that the adult heart contains myocardial progenitor cells which can be recruited in an attempt to replace the injured
myocardium has sparkled interest towards novel molecules capable of improving the differentiation of these cells. In this context, the
peptide hormone relaxin (RLX), recently validated as a cardiovascular hormone, is a promising candidate. This study was designed to
test the hypothesis that RLX may promote the growth and maturation of mouse neonatal immature cardiomyocytes in primary culture.
The cultures were studied at 2, 12, 24 and 48 hrs after the addition of human recombinant H2 RLX (100 ng/ml), the main circulating
form of the hormone, or plain medium by combining molecular biology, morphology and electrophysiology. RLX modulated cell prolif-
eration, promoting it at 2 and 12 hrs and inhibiting it at 24 hrs; RLX also induced the expression of both cardiac-specific transcription
factors (GATA-4 and Nkx2-5) and cardiac-specific structural genes (connexin 43, troponin T and HCN4 ion channel) at both the mRNA
and protein level. Consistently, RLX induced the appearance of ultrastructural and electrophysiological signs of functionally competent,
mature cardiomyocytes. In conclusion, this study provides novel circumstantial evidence that RLX specifically acts on immature car-
diomyocytes by promoting their proliferation and maturation. This notion suggests that RLX, for which the heart is both a source and
target organ, may be an endogenous regulator of cardiac morphogenesis during pre-natal life and could participate in heart regenera-
tion and repair, both as endogenous myocardium-derived factor and exogenous cardiotropic drug, during adult life.
Keywords: relaxin • cardiomyocytes • proliferation • maturation
Introduction
Ischaemic heart disease and related cardiac failure affect an ever-
increasing number of participants, depending on the ageing of
population and elongation of life expectation, with a mean 5-year
survival of 50–70% [1]. This is the main reason for the interest in
the development of new therapeutic strategies aimed to regenerate,
at least in part, the injured myocardium and to prevent or delay the
progression of cardiac failure. Until recently, the myocardium has
been considered a terminally differentiated tissue, without 
self-renewal potential. Therefore, attempts to replace the demised
cardiomyocytes have been mainly based on the administration of
exogenous stem cells, relying on their ability to settle into the 
diseased host myocardium and to differentiate into the cellular
constituents of the heart. However, concerns remain as to whether
these approaches can provide enough new myocyte mass to
restore the mechanical function of the heart [2]. The recent
demonstration that the adult heart contains a pool of cardiac stem
cells [3,4], both in normal and pathological conditions, has 
dramatically changed the traditional view of the heart as a post-
mitotic organ. The identification of spontaneous myocardial
regeneration after ischaemic injury [3,5] indicates that endoge-
nous cardiac progenitor cells, located in the viable myocardium
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surrounding the infarcted area, can be recruited in an attempt to
replace the dead myocardium. However, this phenomenon is not
functionally relevant, conceivably because the myocardial progen-
itors in the adult heart have an intrinsically low regenerative poten-
tial and are operating in an unfavourable environment, as that
occurring in the post-infracted myocardium [6]. In principle, the
persistence of a pool of cardiac stem cells in the adult heart pro-
vides the background for possible therapeutic approaches alterna-
tive to exogenous stem cell transplantation [7]. Therefore, studies
aimed at testing molecules potentially capable of improving the
recruitment, self-renewal and in situ differentiation of resident car-
diac progenitors are topical and clinically relevant. In this context,
the peptide hormone relaxin (RLX) emerges as a promising candi-
date. RLX, best known for its effects on reproduction [8], has been
recently validated as a cardiovascular hormone [9–12]. In fact,
RLX is produced by cardiomyocytes [13–15] and binds to specific
myocardial receptors [13,16–18]. On these grounds, RLX was
hypothesized to play a role in cardiac development during
intrauterine and neonatal life [13]. Of interest, human recombinant
RLX has been recently proven an useful drug in patients with acute
cardiac failure, as it was capable of improving key parameters of
circulatory dysfunction [19–21]. The mechanisms underlying the
functional improvement remain obscure, but conceivably are
diverse and include the ability of RLX to exert direct inotropic
effects, improve blood supply and decrease ventricular stiffness
due to improved myocardial remodelling [12].
Based on the above considerations, in this study we aimed at
extending the current knowledge on the cardiotropic effects of
RLX by investigating the intriguing hypothesis that this hormone
could also influence the growth and maturation of resident
myocardial progenitor cells. To test this hypothesis, we used an in
vitro model of immature cardiomyocytes isolated from neonatal
mouse hearts [22], whose in vitro pattern of maturation has been
well characterized in our previous studies [23].
Materials and methods
Cell culture
Primary cultures of mouse ventricular immature cardiomyocytes were pre-
pared from hearts of 1-day old newborn CD1 albino mice (Harlan,
Correzzana, Italy) following the protocol used for the cardiac beating assay
[22], with minor modifications [23]. This is a well-established method to
obtain myocardium-specific cell cultures, similar to the so-called cardios-
pheres, which are well-suited for functional studies. Briefly, hearts were
quickly excised, the atria were cut-off and the ventricles minced and
digested at 37C for 45 min. in calcium-free HEPES-buffered Hanks’ solu-
tion, pH 7.4, containing 100 g/ml type II collagenase and 1X pancreatin
(Invitrogen, Carlsbad, CA, USA). To reduce the harvest of non-myocardial
cells, the tissue lysate was filtered through a 70 m cell strainer (Millipore,
Billerica, MA, USA) and pre-plated for 1 hr. The myocyte-enriched cells
remaining in suspension were plated on glass cover slips placed in 35-mm
tissue culture dishes for the confocal microscopy studies, or multi-well
plates for the other experimental purposes. Culture supports were pre-
coated with 1.5% gelatin for 30 min. Cardiomyocytes were cultured in
DMEM containing 10% horse serum, 5% foetal bovine serum, and 1 gen-
tamycin (Roche Molecular Biochemicals, Indianapolis, IN, USA). By this
procedure, the cultures are composed of approx. 96% cardiomyocytes, as
judged by vimentin immunofluorescence staining to identify residual fibrob-
lasts, coronary endothelial and endocardial cells [23]. Moreover, these cells
have been shown to express the specific RLX receptor RXFP1 [23]. Twelve
hours after plating, the culture medium was changed and added with human
recombinant H2 RLX, the main circulating form in human beings [8], kindly
provided by Prof. Mario Bigazzi (Foundation for the Study of Relaxin in
Cardiovascular and Other Diseases, Prosperius Institute, Florence, Italy), at
the concentration of 100 ng/ml. This dose was selected as it was found to
have marked biological effects in previous studies on isolated mouse car-
diomyocytes [24] as well as in models of cardiac ischaemia-reperfusion in
vitro and in vivo in different animal species [25,26]. The cultures were stud-
ied at 2, 12, 24 and 48 hrs after the RLX addition. Control cardiomyocyte
cultures, not treated with RLX, were also studied at the same time points.
Cell proliferation analysis by 3H-thymidine 
incorporation
To evaluate whether RLX affected cell proliferation, freshly isolated cells
were seeded in 24-well plates, approximately 104 cells/well, and cultured
for 2, 12, 24 and 48 hrs in DMEM in the absence or presence of RLX 
(100 ng/ml). After the incubation, the medium was replaced with Hank’s
Balanced Salt Solution (HBSS; Gibco-Invitrogen, S.Giuliano Milanese,
Italy) containing 18.5 kBq/ml (0.5 Ci/ml) 3H-thymidine for 1 hr at 37 C.
The medium was then removed, the cultures washed with plain HBSS and
DNA precipitated with cold 3% TCA and extracted with 1 ml of 0.3M NaOH.
The recovered radioactivity was measured in a  counter (1900 TR;
Packard, Zurich, Switzerland). The experiments were performed in tripli-
cate and the values expressed as dpm/mg of proteins, the latter measured
with the bicinchoninic acid (BCA) assay (mean  S.E.M.).
Based on these results, 3H-thymidine incorporation by cardiomyocytes
in the earlier phases of active growth was also investigated by histoautora-
diography. Briefly, cardiomyocytes seeded onto glass slides were grown
for 2 and 12 hrs in DMEM in the absence or presence of RLX (100 ng/ml).
After the incubation, the medium was replaced with (HBSS; Gibco-
Invitrogen) containing 37 kBq/ml (1 Ci/ml) 3H-thymidine for 1 hr at 
37 C. Then, the cells were fixed in Carnoy’s fixative for 20 min., the slides
were washed overnight in distilled water, dipped in photographic emulsion
(K5; Ilford Photo, Mobberley, UK) at 50C, dried at 20C, and exposed in
the dark for 7 days at 4C. After exposure, the slides were immersed in D19
developer (1:1 in distilled water; Kodak Ltd., Milan, Italy) for 8 min. at 20C.
Development was stopped by immersion in 1 M acetic acid for 2 min at
20C and the slides were fixed for 6 min. at 20C in Amfix (1:5 in distilled
water; May and Baker, Eccles, UK), rinsed for 1 hr in distilled water, coun-
terstained with haematoxylin, dehydrated and mounted in Eukitt medium.
The percentage of labelled cells over total cells was calculated on 10 ran-
domly chosen microscopical fields viewed with a 40 objective by a
trained observer who was unaware as to the experimental group of the
autoradiographic slides he was scoring.
RNA isolation
Total RNA was isolated by extraction with TRIzol Reagent (Invitrogen Life
Technologies, Grand Island, NY, USA), according with the manufacturer’s
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instructions. Potential contaminating DNA was removed with DNase
(Deoxiribonuclease I; Sigma-Aldrich, Milan, Italy) prior to the reverse tran-
scription (RT) reaction. Concentration and purity of extracted RNA were
evaluated prior and after the DNase treatment by spectrophotometry, by
measuring the absorbance at 260 and 280 nm wavelength. The absence of
RNA degradation was confirmed by agarose gel electrophoresis with ethid-
ium bromide staining.
Real-time PCR
One microgram of total RNA was reverse transcribed to single-stranded
cDNA using the commercially available i-script cDNA Synthesis Kit
(BioRad, Foster City, CA, USA), according to the manufacturer’s instruc-
tions. Samples were incubated at 25C for 5 min., at 42C for 30 min. and
then at 85C for 5 min. in a thermal cycler. Negative controls of the RT were
performed by omitting the enzyme or by substituting the RNA for sterile
RNAse-free water, to control for genomic DNA and RNA contamination,
respectively. Quantitative real-time PCR was carried out using the ABI
Prism 7500 Sequence Detection System instrumentation (Applied
Biosystems, Carlsbad, CA, USA) and Taqman gene expression assay
reagents (Applied Biosystems), consisting in a specific set of primers and
a fluorogenic internal probe. The expression of five-key target genes
involved in cardiomyocyte differentiation was quantitated in comparison
with the housekeeping gene GAPDH (Table 1). PCR amplifications were
performed in Optical 96-well plates (Applied Biosystems) on cDNA sam-
ples corresponding to a final RNA concentration of 50 ng. PCR was per-
formed in a total volume of 20 l containing 2 Taqman Universal PCR
Master mix (Applied Biosystems) and 20 Taqman gene expression assays.
Reaction conditions were as follows: 50C for 2 min., 95C for 10 min., 
followed by 40 cycles at 95C for 15 s alternating with 60C for 1 min. PCR
amplifications were run in triplicate. Blank controls, consisting in no tem-
plate (water) or RT-negative reactions, were performed in each run. The
results of the real-time PCR data were represented as Ct values, where Ct
was defined as the PCR threshold cycle at which amplified product was
first detected. Ct values were analysed using 2		Ct method. All values
were normalized to the GAPDH housekeeping gene expression (Table 1).
Confocal immunofluorescence microscopy
Paraformaldehyde-fixed cells grown onto glass cover slips were immunos-
tained with the following primary antibodies: goat polyclonal anti–GATA-4
(1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse monoclonal
anti-connexin 43 (Cx43, 1:200; Chemicon, Temecula, CA, USA); mouse
monoclonal anti-cardiac troponin T (cTnT, 1:100; LabVision, Fremont, CA,
USA); rabbit polyclonal anti-hyperpolarization– activated cyclic nucleotide-
gated channel HCN4 (1:100; Santa Cruz). Immune reaction was revealed
using the appropriate Alexa-conjugated secondary antibodies (1:100;
Molecular Probes, Eugene, OR, USA). Negative controls were performed
by replacing the primary antisera with corresponding non-immune sera
from the same animal species. Cells were examined with a Leica TCS SP5
confocal laser scanning microscope (Leica Microsystem, Mannheim,
Germany) equipped with a Leika PlanApo 63 oil-immersion objective and
a HeNe/Argon laser source for fluorescence measurements and with differ-
ential interference contrast (DIC) optics for transmission images. A series
of optical sections (1024  1024 pixels) at intervals of 0.8 m were
obtained and superimposed to create a single composite image.
Densitometric analysis of the intensity of the immunofluorescent staining
for the assayed markers was performed on digitized images of the cultures
using the free-share ImageJ software (http://rsbweb.nih.gov/ij). Briefly, a
test area of 100 m2 was used to measure 5 volumes of interest, 6 m
thick, in each confocal stack. Five confocal stacks were selected at random
for each experimental condition. The mean  S.E.M. optical density was
then calculated.
Transmission electron microscopy
Cardiomyocytes grown for 48 hrs in the presence or absence of RLX 
(100 ng/ml) were pelleted by centrifugation, fixed in 4% glutaraldehyde,
post-fixed in 1% osmium tetroxide and embedded in Epon 812. Ultrathin
sections were stained with uranyl acetate and alkaline bismuth subnitrate
and examined under a JEM 1010 electron microscope (Jeol, Tokyo, 
Japan) at 80 kV.
Electrophysiology
The electrophysiological features of cardiomyocytes were investigated by
whole-cell patch-clamp, as described [23, 24], at 24 and 48 hrs. In partic-
ular, we evaluated: (i) occurrence of rhythmic action potentials (APs); (ii)
inward Na current, INa,; (iii) T-type (ICa,T) and L-type (ICa,L) Ca2 currents;
(iv) depolarization-activated transient outwards K current Ito; (v) the
inward rectifier IK1; (vi) the pacemaker current If. The patch-clamp assay
was performed using micromanipulator-operated micropipettes connected
to an Axopatch 200B amplifier (Axon Instruments, Molecular Devices,
Sunnyvale, CA, USA). Cells to be analysed were selected among the small-
est cell clusters (max. five cells). Both voltage-clamp and current-clamp
modes were used. Whole-cell recording was established in the voltage-
clamp mode and compensation for the pipette capacitance was performed
before switching into the current-clamp mode to record the AP of sponta-
neously beating cells. In our experimental protocol, cells were allowed to
grow for 24 and 48 hrs and establish physiological cell–cell contacts and
gap junctional communications, which are required for cardiomyocyte
maturation. Just before performing the recordings, heptanol (1 mM) was
added to block gap junctional communication. In this way, the cells were
© 2011 The Authors
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only uncoupled during the electrophysiological experiments. Protocol gen-
eration and data acquisition were controlled by using two output and input
of the A/D-D/A interfaces (Axon Digidata 1200; Molecular Devices) and
Axon Pclamp 9 software (Molecular Devices). Unless otherwise stated, the
used reagents were from Sigma-Aldrich. The experiments were carried out
in normal Tyrode (NT) bath solution of the following composition (mM):
NaCl 140, KCl 5.4, CaCl2 1.5, MgCl2 1.2, glucose 5.5, HEPES/NaOH 5, at
room temperature. The choice to perform the experiments at a temperature
below the physiological 37C aimed at extending the life span of the cells
during the experiments, as well as improving the recording of the details
of current traces, particularly the fastest currents. To test high-
voltage–activated Na channel sensitivity, we used tetrodotoxin (TTX, 
1 M). When outward K currents had to be suppressed, experiments
were performed in 20 mM tetraethylammonium (TEA) bath solution com-
posed by (mM): 122.5 NaCl, 2 CaCl2, 20 TEA-OH, 10 HEPES. The K chan-
nel blocker 4-aminopyridine (2 mM) was also used to test for the occur-
rence of 4-aminopyridine–sensitive transient outward K current, Ito. Ca2
currents were recorded in Na-and K-free TEA-Ca2 bath solution con-
taining (mM): 10 CaCl2, 145 TEA bromide, 10 HEPES. In turn, 10 M
nifedipine were added to block L-type Ca2 channels. To record IK1 or If, 
4 mM Cs or 0.5 mM Ba2 was applied to the bath solution [27]. The pH
of the bath solution was adjusted to 7.4 with NaOH. Patch pipette filling
sterile solution contained (mM): 130 KCl, 10 NaH2PO4, 0.2 CaCl2, 1 EGTA, 
5 MgATP, 10 HEPES, adjusting pH to 7.2 with KOH. The rapid inward Na
(INa) and Ca2 currents were evoked by 1 sec. voltage pulses ranging from
80 to 50 mV in 10 mV increments applied from a holding potential
(HP) of 90 mV. The K current (IK,tot) flowing through delayed rectifier
channels was elicited in voltage clamp conditions from an HP of 60 mV
to block Na current (INa) and T-type Ca2 current (ICa,T) and in the pres-
ence of nifedipine to block L-type Ca2 current (ICa,L). Pulse stimulation
protocol consisted of voltage steps in 10 mV increments ranging from
80 to 50 mV. The Ito was elicited by 1 sec. voltage steps from 40 
to 50 mV applied from an HP of 60 mV, being INa and T-type Ca2
current inactivated. The inward rectifier current (IK1) was evoked by ramp
voltage-clamp pulses applied from an HP of 120 to 40 mV at a rate of
100 mV/sec. The If pacemaker current was evoked by hyperpolarizing
steps ranging from 30 to 150 mV in 20-mV increments applied from a
HP of 30 mV. APs were recorded by switching the amplifier to current
clamp mode. The passive membrane capacitance Cm was used as an index
of the membrane surface area, considering the specific value of 1 F/cm2.
In this way, as Cm ranged between 58 and 118 pF in the different experi-
mental conditions (Table 2, first line), the calculated surface area varied
from 58 to 118 106 cm2. Data are reported as current density (I/Cm) and
specific conductance (G/Cm) to allow comparison of test currents recorded
from different cells. The steady-state ionic current of activation was 
evaluated by the formula: Ia (V) 
 Gmax (V Vrev)/{1  exp [(Va  V)/ka]}
and steady-state inactivation of If by the formula: Ih (V ) 
 I / {1  exp[
(Vh  V)/kh]}, where Gmax is the maximal conductance for the Ia, Vrev, is
the apparent reversal potential, Va and Vh are the potentials that elicit,
respectively, the half-maximal activation and inactivation values, ka and kh
are the steepness factors.
Statistical analysis
Statistical analysis of differences between the control and the RLX-treated cul-
tures at the assayed time points was performed using one-way ANOVA and post
hoc test. The differences between paired values of the real-time PCR assay
were analysed by Student’s t-test. Calculations were performed using the
GraphPad Prism 4.0 statistical software (GraphPad, San Diego, CA, USA).
Results
The cultured cardiomyocytes were examined at different time
points (2, 12, 24 and 48 hrs) from the addition of culture medium
in the presence or absence of RLX by phase-contrast light
microscopy (data not shown). At the earliest time, they appeared
as scattered round- or polyhedral-shaped cells with no sponta-
neous beating, consistent with their nature of immature cardiomy-
ocytes. From 12 hrs onwards, the isolated cells spontaneously
tended to gather into aggregates which contracted rhythmically
and became larger with time, as previously reported [23]. RLX did
not appear to induce major morphological changes of the overall
appearance of the cultures, apart from a larger size of the car-
diomyocyte aggregates and an increased number of the stripe-like
cells at the later time points. These effects of RLX were conceiv-
ably ascribable to its ability to stimulate cell proliferation in 
the short term. In fact, as revealed by 3H-thymidine incorporation
(Fig. 1A and B), RLX significantly increased the amount of cycling
cells at the earlier time points, especially upon the 12-hr 
incubation. On the other hand, at 24 hrs, RLX significantly reduced
the amount of cycling cells, whereas it did not induce appreciable
changes at 48 hrs. Histoautoradiography (Fig. 1B) confirmed 
that RLX, at the earlier time points, markedly stimulated cell 
proliferation: in fact, the percentage of cycling cells was signifi-
cantly increased at 2 hrs (5.4  1.1 versus 2.3  0.6 in the 
controls, n 
 10, P  0.02 by Student’s t-test) and even higher 
at 12 hrs (7.4  1.2 versus 1.7  0.4 in the controls, n 
 10, 
P  0.001 by Student’s t-test).
The real-time PCR analysis revealed that RLX up-regulated the
expression of key genes involved in myocardial differentiation
(Fig. 2). In particular, as compared with the control cultures, 
the transcripts for myogenic transcription factors GATA-4 and
Nkx2-5, which are required to induce the expression of cardiac-
specific structural genes during cardiomyocyte maturation
[28,29], were significantly increased by RLX by the 24- and 
48-hrs time points, with an overt inverse relationship with cell
growth stimulation. Consistent with these findings, the transcript
for Cx43, which is crucial for the intercellular coupling and trans-
mission of the electrical excitation among cardiomyocytes
[30,31], was significantly enhanced by RLX starting from 24 hrs
onwards. Moreover, the mRNA levels of cTnT, a typical sarcom-
eric protein, was also increased by RLX, reaching a maximum at
48 hrs. Finally, the transcript for HCN4, a hyperpolarization-acti-
vated cyclic nucleotide-gated mixed Na/K channel involved in
cardiac pace-making If current [32] was also affected by RLX,
showing significantly increased expression at any time point
assayed, with a peak at 24 hrs.
In keeping with the above findings, the immunofluorescence
analysis revealed that RLX enhanced the expression of represen-
tative differentiation proteins, including GATA-4, Cx43, cTnT and
HCN4 (Fig. 3). In particular, GATA-4 was expressed in both the
cytoplasms and the nuclei, consistently with its synthesis and
subsequent translocation into the nucleus. Densitometric quantifi-
cation of the immunostaining showed that, upon a 2-hr incubation,
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there were no appreciable differences between the control and the
RLX-treated cultures, whereas marked, statistically significant
increase in the immunoreactivity for the noted proteins was
detected upon a 48-hr incubation with RLX (Fig. 3).
The ultrastructural analysis confirmed that RLX promotes
 cardiomyocyte maturation. In fact, the cardiomyocytes grown for
48 hrs in the absence of RLX mostly showed an organellular
complement typical of immature cells, containing free polyribo-
somes, some dilated rough endoplasmic reticulum (RER) 
cisternae, diffuse cytoskeletal components, sparse glycogenic
fields and small, round-shaped mitochondria (Fig. 4A). Instead, at
the same end-point, the RLX-treated cardiomyocytes mostly
 displayed muscle cell features, with numerous leptomeres, that is
cross-banded structures composed of periodically arranged elec-
tron-dense bands bridged by 5-nm-thick filaments [33], and
abundant mitochondria with packed cristae and condensed
matrix (Fig. 4B). Cells at a more advanced stage of striated
 muscle maturation, containing myofibrillar structures, rod-
shaped mitochondria with electron-dense matrix granules and
intercellular junctions featuring rudimentary intercalated discs
were seldom encountered in the RLX-treated cultures, but not in
the control ones (Fig. 4C).
© 2011 The Authors
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Table 2 Membrane capacitance (Cm) and activation Boltzmann parameters of INa, ICa,T, ICa,L and If currents in the cardiomyocytes grown for 24
and 48 hrs in the absence or the presence of RLX
Ip: data of the peak current at the voltage eliciting the maximal current; Ito: data at 50 mV; IK1: data at 120 mV; If: data at 150 mV; ICa,T evalu-
ated in the presence of nifedipine, and ICa,L evaluated after detracting ICa,T from the total Ca2 current (ICa,tot, see also Fig. 7D). Significance of
 differences (one-way ANOVA): RLX versus RLX, *P  0.05, **P  0.01, ***P  0.001; 24 hrs versus 48 hrs, §P  0.05, §§P  0.01, 
§§§P  0.001. Data are mean  S.E.M. of the values from 26 to 35 cardiomyocytes.
Currents Parameters RLX (24 hrs) RLX (24 hrs) RLX (48 hrs) RLX (48 hrs)
Cm (pF) 58  5 75  8** 958 §§§ 118  12** §§§
INa Ip (pA/pF) 325  30 500  55** 40042§§ 620  61** §§§
Gm (nS/pF) 4.5  0.3 8.1  0.6 ** 5.10.4 § 9.8  0.9** §§
Va (mV) 26.1  2.1 27.2  2.8 27.52.7 30.3  3.1* §
Ka (mV) 6.4  0.4 6.2  0.4 * 6.2  0.4 5.7  0.4* §
Vr (mV) 47.4  4 47.0  4 48.6  4 47.1  5
ICa,T Ip (pA/pF) 2.0  0.2 2.90.3*** 2.4  0.2 § 3.5  0.3*** §§
Gm (pS/pF) 20.1  2.1 30.1  2.4 ** 20.3  2.1 40.2  3.3*** §§
Va (mV) 37.0  3.6 36.7 3.8 36.53.2 37.2  4.2
Ka (mV) 7.1  0.5 6.9 0.5 6.90.5 6.6  0.5
Vr (mV) 68.4  5 67.1  4  69.1  4 67.7  4
ICa,L Ip (pA/pF) 8.1  0.8 16  1.2** 110.9 §§ 251.6** §§§
Gm (pS/pF) 100  10.3 159.7  15.5 ** 150.2  12.2§§§ 251.3  20.2*** §§§
Va (mV) 11.8  1.1 13.2  1.2 13.21.2 § 14.6  1.2* §
Ka (mV) 7.5  0.6 6.9  0.5 * 7.1  0.6 5.9  0.5** §§
Vr (mV) 69.4  5 67.4  4 68.1  4 69.1  4
Ito Ito,50 (pA/pF) 5.6  0.5 8.3  0.7** 7.1  0.6 §§ 11  0.9** §§
IK1 IK1,-120 (pA/pF) 7.5  0.6 9.5  0.8** 11.40.9 §§ 13.5  1.1** §§§
If If,-150 (pA/pF) 5.0  0.3 5.5  0.3* 6.80.5 §§ 8.1  0.6** §§§
Gm (pS/pF) 33.6  3.5 38.5  4.2 * 46.2  3.8 §§ 55.4  4.4** §§§
Va (mV) 93.1  9.3 92.2  9.4 92.2  8.4 92.2  8.4
Ka (mV) 16.4  0.3 16.1  0.4 16.1  0.4 15.6  0.4
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Once assessed that RLX, at 24 and 48 hrs, was capable of
prompting the cardiomyocytes towards a biochemically mature
phenotype, we next investigated by electrophysiology, at the same
time points, whether these cells would also acquire a functional
electrical phenotype. By whole-cell patch in current clamp 
mode, the control cardiomyocytes, assayed at 24 hrs, showed
spontaneous rhythmic APs with a slow depolarization phase 4
(pacemaker current) from a maximal diastolic potential (MDP) 
of 61.2  5 to a voltage threshold for AP of 46.0  5 mV
[Figure 5A(a)]. When recording the membrane currents by voltage
© 2011 The Authors
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Fig. 1 Cell proliferation analysed at the noted time points from the addition
of fresh culture medium, alone (open columns) or with RLX added (striped
columns): (A) 3H-thymidine incorporation and -counting (DPM: disinte-
grations per minute); (B) histoautoradiography of 3H-thymidine–labelled
cardiomyocytes. RLX significantly increases the number of cycling cells at
2 and 12 hrs. On the other hand, the cells’ growth rate decreases at 24 hrs
in comparison with the control cultures and remains unchanged at 48 hrs.
Significance of differences (one-way ANOVA, n 
 3): *P  0.05; **P 
0.01. Bar (lower right) 
 20 m.
Fig. 2 Quantitative real-time PCR analysis showing the effects of RLX on
the expression of mRNAs for the noted myocardial markers at the different
time points. The columns represent fold changes over the corresponding
values of the control cultures, assumed as 1. Significance of differences
(Student’s t-test, n 
 3): *P  0.05 versus the controls.
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clamp to elucidate the ionic basis for AP dynamics (Fig. 5B–D), the
cardiomyocytes showed: (i) a prominent inward Na current, INa,
in the first 3–4 msec. of the pulse starting from a threshold of
49.5  4 mV, blocked by TTX (Fig. 5B and D); (ii) two Ca2 cur-
rents which, based on voltage dependence and nifedipine sensitiv-
ity, were identified as the transient T-type (ICa,T) and L-type (ICa,L)
Ca2 currents: ICa,T was evoked from 60 mV, whereas ICa,L was
elicited from 30 mV with a slower activation and inactivation rate
(Fig. 5C(a) and D); (iii) typical K currents of mature cardiomy-
ocytes [23], including fast transient outward Ito (Fig. 6A) blocked
by 2 mM 4-aminopyridine, and inward rectifier IKl recorded with
external solution containing 3 mM Cs (Fig. 6B); (iv) the pace-
maker current If recorded in external solution containing 0.5 mM
of Ba2 [Fig. 6C(a–c)]. Despite the occurrence of If, which fits well
with the expression of HCN4 channel, the cultured cardiomyocytes
should not be identified as pacemaker cells: in fact, they did show
a small early upstroke of the AP, which is lacking in authentic
pacemaker cells because of defective or absent expression of Na
channels. As expected, the cardiomyocytes underwent sponta-
neous time-dependent maturation, as judged by: (i) the amplitude
of AP overshoot, which increased from 12  3 mV (24 hrs) to 
25  3 mV (48 hrs; P  0.01); (ii) AP duration quantified at 90%
repolarization, which decreased from 128  13 msec. (24 hrs) to
105  10 msec. (48 hrs; P  0.05); (iii) beating rate, which
increased from 72  9 (24 hrs) to 110  15 beats/min. (48 hrs;
P  0.01). Moreover, at the later time point (48 hrs), the car-
diomyocytes showed an increase in membrane capacitance (Cm),
an indirect index of cell size (Table 2) INa, ICa,T and ICa,L current size
and GNa, GCa,T and GCa,L conductance (Fig. 5B–D, Table 2), and If,
Ito and IKl amplitudes (Fig. 6A–C, Table 2).
Fig. 3 Representative merged differential interference contrast and confocal immunofluorescent micrographs of cardiomyocytes cultured for 2 and 
48 hrs in the absence or presence of RLX. Immunoreactivities for the different antigens are shown in pseudo-colours. There is a visible increase in the
immunoreactivity for the noted antigens upon a 48-hrs incubation with RLX. GATA-4–positive nuclei are indicated by asterisks. Bar (upper left) 
 16 m.
The right panels show the computer-aided densitometry of the immunostaining for the noted myocardial marker proteins. Significance of differences 
(one-way ANOVA, n 
 5): *P  0.05 and **P  0.01 versus RLX 2 hrs; P  0.05 and P  0.001 versus RLX 2 hrs; #P  0.05, ##P  0.01
and ###P  0.01 versus RLX 48 hrs.
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Of note, compared with the time-matched control cultures, the
RLX-treated cardiomyocytes showed significantly higher values of
the voltage-gated currents INa, ICa,T, ICa,L and GNa, GCa,T, GCa,L con-
ductance (Fig. 5B(b), C(b) and D; Table 2), If, Ito and IKl amplitude
(Fig. 6A–C; Table 2) and significantly greater membrane capaci-
tance, Cm (Table 2). Notably, RLX modified the voltage sensitivity
of INa and ICa,L currents because Va values were shifted towards
more negative potential, and Ka values were decreased. Finally,
compared with the controls, the spontaneous firing rate of 
the RLX-treated cardiomyocytes increased to 120  12 (24 hrs; 
P  0.01) and 140  14 beats/min. (48 hrs; P  0.01; Fig. 5A b),
in keeping with the reported chronotropic effects of the hormone
[34]. Careful analysis of the reported electrophysiological findings
supported the view that RLX can promote cardiomyocyte matura-
tion towards the ventricular phenotype. In particular, this was 
suggested by: (i) the greater amplitude of the early upstroke of the
AP (from 12  3 to 32  6 mV, P  0.01 and from 25  3 to 
36  6 mV, P  0.05, at 24 and 48 hrs, respectively) and of AP
itself (from 60  5 to 80  7 mV, P  0.01 and from 70  7 to
85  7, P  0.05, at 24 and 48 hrs, respectively) compared with
the controls, confirmed by the greater Gm value of the Na current;
(ii) the Va features of T-type and L-type Ca2 currents, whose val-
ues were more positive than those of typical atrial cardiomyocytes
[35,36]; (iii) the increase of IK1 (Table 2, Fig. 6B), which was
related to a significant decrease of AP duration quantified at 90%
repolarization (24 hrs: 128  13 versus 112.8  10 with and with-
out RLX, P  0.05; 48 hrs: 105.1  9 versus 98.2  8 with and
without RLX, P 0.05) and to a more hyperpolarized MDP (24 hrs:
61.2  5 versus 62.8  5 with and without RLX; 48 hrs:
64.1  5 versus 70.2  5 with and without RLX, P  0.05).
IK1 and If exerted opposite effects on MDP and diastolic depolariza-
tion rate, in agreement with the counteracting roles of repolarizing
IK1 and depolarizing If currents [27]. Hence, the size increase of If
induced by RLX reduced in part the changes of MDP induced by
IK1. However, the role of IK1 on MDP prevailed on If, as the sizes of
IK1 were 25–50% greater that those of If (Table 2).
Discussion
As in other organs provided with a stem cell pool, the normal heart
is thought to harbour undifferentiated, quiescent cardiac stem
cells (CSC), mainly located in epicardial ‘cardiogenic niches’ and
characterized by low or null proliferative potential. Once recruited
by appropriate stimuli, these cells may enter the cell cycle and give
rise to immature cardiomyocytes, or cardiac precursors, charac-
terized by higher proliferative potential and restricted commitment
to the myocardial differentiation lineage [3,4]. Knowledge of the
endocrine/paracrine factors controlling growth and differentiation
of cardiomyocyte precursors is of pivotal interest to understand
the physiological mechanisms involved in cardiac development, as
well as to identify and validate new therapeutic strategies for the
failing heart. In this context, the present in vitro study offers novel
circumstantial evidence that the hormone RLX specifically acts on
immature cardiomyocytes, which express the RLX receptor RXFP1
[23], by modulating proliferation and promoting maturation. This
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Fig. 4 Representative electron micrographs of cardiomyocytes cultured for 48 hrs in the absence (A) or presence of RLX (B, C). (A) An immature 
control cardiomyocyte showing round mitochondria (inset) and glycogen fields (g). (B) A more mature RLX-treated cardiomyocyte showing cytoplasmic
leptomeres (asterisks, lower inset) and round mitochondria with densely stacked cristae and electron-dense matrix granules (upper inset, arrows). (C)
Another mature RLX-treated cardiomyocyte showing myofibrils and rod-shaped mitochondria with electron-dense matrix granules (inset, arrows). The
asterisks label the leptomeres in an adjacent cell. Bar (left) 
 1 m.
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notion suggests that RLX, for which the heart is both a source and
target organ [9–12], may be an endogenous regulator of cardiac
morphogenesis during pre-natal life, as previously suggested
[13], and could participate in heart regeneration and repair during
adult life, both as endogenous myocardium-derived factor and
exogenous cardiotropic drug.
This study shows that RLX had a biphasic effect on cardiomy-
ocyte growth, consisting in a stimulation at the earlier time points
© 2011 The Authors
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Fig.  5 Electrophysiological features of the
neonatal cardiomyocytes cultured for 24 and 
48 hrs in the absence (a) or presence of RLX
(b). (A) Representative spontaneous action
potentials recorded in current clamp mode at 
24 hrs. (B) INa traces and (C) ICa traces recorded
in voltage-clamp mode at 24 hrs: T indicates
transient T-type ICa. (D) Boltzmann functions
depicting I–V curves for INa peak, total ICa,tot and
T-type Ca2 currents, recorded in the presence
of nifedipine at 24 and 48 hrs. The related
Boltzmann parameters and the statistical analy-
sis are reported in Table 2. Data are mean values
from 26 to 35 different cells.
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(2 and 12 hrs) and a subsequent growth rate reduction in compar-
ison with the control cultures (24 hrs), concurrently with the peak
in the expression of key markers of cardiac muscle differentiation.
In the longer time (48 hrs), when cells attained a more advanced
degree of maturation, RLX had no more effects on cell growth.
This particular behaviour of RLX is consistent with the assumption
that RLX could be a physiologic regulator of cardiac cell differen-
tiation, being able to promote growth of cardiomyocyte precursors
and then support their maturation towards a functional phenotype.
Of note, a similar biphasic effect of RLX on cell growth was previ-
ously reported in hormone-responsive MCF-7 breast adenocarci-
noma cells, in which down-regulation of proliferation was associ-
ated with the exhibition of a more differentiated phenotype by the
target cells [37,38].
The reported effects of RLX on cardiomyocyte maturation
involve the activation of the typical cardiac muscle transcription
factors GATA-4 and Nkx2-5, which are known to play important
roles in transducing nuclear events that modulate cell lineage dif-
ferentiation during the development of mature cardiomyocytes
[28,29]. In addition to regulating cell growth and differentiation,
there is increasing evidence that GATA-4 and Nkx2-5 also control
cell survival by inducing an anti-apoptotic phenotype [39,40].
Although our study does not address this issue, it is tempting to
speculate that the RLX-induced GATA-4 and Nkx2-5 up-regulation
in the cardiomyocytes, besides favouring the recruitment of car-
diomyocyte precursors involved in heart repair, may also con-
tribute to increase their resistance to the hostile local environment
of the diseased myocardium, thereby improving their regenerative
potential. In this context, it is worth noting that exogenously
administered RLX has been shown to reduce the extent of non-
viable myocardium in ischaemia-reperfusion animal models
[26,41] and genetic transduction of C2C12 myoblasts to secrete
RLX increases their engraftment and survival in the post-infarcted
hearts of swine and rats [42,43].
We also investigated the nuclear transcriptional activity down-
stream GATA-4 and Nkx2-5: consistent with the above findings,
© 2011 The Authors
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Fig. 6 Electrophysiological features of Ito, IK1 and
If currents in the neonatal cardiomyocytes cul-
tured for 24 and 48 hrs in the absence (control)
or presence of RLX. I–V plots of: (A) outward Ito,
and (B) transient inward rectifier IK1, evaluated
by a voltage ramp protocol. (C) If trace currents
in cardiomyocytes cultured for 24 hrs in the
absence (a) or presence of RLX (b) and the rel-
evant I–V plots at 24 and 48 hrs (c). RLX
increases IK1 size by shifting its voltage depend-
ence towards more positive potentials and
enhances the size of Ito and If. The related
Boltzmann parameters and the statistical analy-
sis are reported in Table 2. Data are mean values
from 26 to 35 different cells.
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we found that the expression of cardiac-specific structural genes
encoding for the sarcomeric protein cTnT, the ion channel HCN4
and the gap-junction protein Cx43 was significantly increased in
the RLX-treated cells as compared with the untreated ones.
Moreover, the presence of RLX in the culture medium also stimu-
lated the acquisition of typical ultrastructural signs of striated
muscle differentiation, such as leptomeres and myofibrils, by the
developing cells. It is well known that Cx43 forms intercellular
channels which link the cytoplasmic compartments of adjacent
cardiomyocytes and ensure the efficient and rapid propagation of
electrical impulses [30,31] as well as the transfer of Ca2 and
other signals involved in the regulation of cell proliferation and dif-
ferentiation [44,45]. The present observation that RLX increases
Cx43 expression suggests that this may be a key mechanism of its
growth- and differentiation-promoting effects. Moreover, Cx-43
participates in cellular adaptation to ischaemia [46] and its up-
regulation has been found to enhance stem cell survival and
engraftment in the infarcted heart [47]. These latter findings add
further support to the hypothesis that RLX may render the car-
diomyocyte precursors resistant to the adverse conditions of the
diseased post-ischaemic heart.
The effects of RLX on cardiomyocyte maturation were further
supported by the electrophysiological data. Indeed, the observed
up-regulation of HCN4, a membrane channel playing a major role
in cardiac automatisity [32], induced by RLX fits well with the abil-
ity of the hormone to induce the appearance of If, the typical
HCN4-operated current. The time-course analysis of the behaviour
of the myocardial cell cultures indicated that, soon after isolation
and plating, the cells do not show spontaneous beating: rather,
this feature appears within 12–24 hours of culture, concurrently
with peak HCN4 gene transcription. This suggests that HCN4 is
involved in early maturation steps of the myocardial cells, as
recently reported [48]. It is conceivable that, in the longer times
(which we did not explore in this study), when cardiomyocytes
accomplish their maturation programme, HCN4 is only retained by
the pacemaker cells and tends to disappear in the cells of the
working myocardium. Of note, all the major currents involved in
cardiomyocyte rhythmic electrical activity attain higher amplitudes
(INa, ICa,T, ICa,L, If, Ito and IKl) and conductances (GNa, GCa,T, GCa,L)
upon RLX treatment, with an electrical phenotype reminiscent of
that of ventricular cardiomyocytes. Moreover, the hormone
increases the overall cell size, as judged by the observed increase
in membrane capacitance (Cm).
It should be pointed out that the current in vitro culture model
is composed by a vast majority of bona fide immature cardiomy-
ocytes and a minority of non-muscle cells of the cardiac environ-
ment [23]. Considering that fibroblasts are also known to express
RXFP1 [49], it cannot be ruled that these cells may concur, for
instance by paracrine or juxtacrine mechanisms, to the observed
effects of RLX on cardiomyocyte growth and maturation.
Taken together, the present findings that RLX is capable of mod-
ulating growth and promoting maturation of neonatal cardiomy-
ocytes may be clinically relevant. In fact, evidence has been pro-
vided that RLX is released in blood in patients suffering for chronic
heart failure [14,15]. This may be interpreted as an adaptive
response of the heart to damage and dysfunction. Although RLX
has been attributed direct inotropic effects [50], peripheral and
coronary vascular actions [51,52] and marked anti-fibrotic effects
in post-infarction remodelling [53] which could favourably act on
the failing heart, it cannot be ruled out that this hormone could also
promote the recruitment of dormant myocardial precursor cells in
an attempt to repair the damaged myocardium. This hypothesis is
particularly intriguing, considering that human recombinant RLX
has been demonstrated to have beneficial effects in phase II clini-
cal trials on patients suffering for congestive heart failure [19–21].
It is conceivable that, with appropriate dosage and administration
protocols, RLX may be recognized a valuable therapeutic tool to
enhance the ability of the myocardium to self-regenerate.
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